Breaking News
October 15, 2018 - Innovative brain tumor operation set to tailor to patients’ needs
October 15, 2018 - Findings offer new insight into early changes that occur during AD pathology
October 15, 2018 - Neurons regulating reproductive hormone release have different activity in epileptic mice
October 15, 2018 - More parents are concerned about taking babies swimming in public pools
October 15, 2018 - Health Tip: Know the Risk Factors for Lower Back Pain
October 15, 2018 - Study shows cigarillo flavors enhanced by high-intensity sweeteners
October 15, 2018 - Study traces hospital-acquired bloodstream infections to patients’ own bodies | News Center
October 15, 2018 - Abnormal vision in childhood can affect development of brain areas responsible for attention
October 15, 2018 - Color-changing contact lens could help doctors to monitor eye disease medications
October 15, 2018 - Tobacco heating products cause less staining to teeth than conventional cigarettes
October 15, 2018 - Young adults who are obese can expect to lose up to 10 years in life expectancy
October 15, 2018 - Scientists uncover how proteins meet on the cell membrane
October 15, 2018 - Affordable housing with supportive social services for senior citizens can reduce hospital use
October 15, 2018 - Following a Tissue Sample
October 15, 2018 - Prisoners need drug and alcohol treatments but AA programs aren’t the answer
October 15, 2018 - Andrea Califano and Jordan Orange Elected to National Academy of Medicine
October 15, 2018 - The impending risk of African Swine Fever Virus
October 15, 2018 - Breastfeeding reduces the number of antibiotic-resistant bacteria in infant gut
October 15, 2018 - Researchers develop comprehensive molecular atlas of postnatal mouse heart development
October 15, 2018 - ObsEva SA Presents Clinical Data from Phase III IMPLANT 2 Trial of Nolasiban in IVF at the American Society of Reproductive Medicine (ASRM) Annual Meeting
October 15, 2018 - Engineering teratoma-derived fibroblasts to enhance osteogenesis
October 15, 2018 - Lab study shows effectiveness of potential therapy for treatment-resistant hypothyroidism
October 15, 2018 - JCU study firms up association between diet and depression
October 15, 2018 - Researchers to study the use of CRISPR on human liver on-a-chip platform
October 15, 2018 - Sub-concussive impacts not associated with decline in neurocognitive function
October 15, 2018 - Researchers find potential treatment to halt premature labor and birth
October 15, 2018 - As U.S. suicides rates rise, Hispanics show relative immunity
October 15, 2018 - FDA Issues a Complete Response Letter to Acacia Pharma for Barhemsys
October 15, 2018 - Photoactive bacteria bait may help in fight against MRSA infections
October 15, 2018 - Increasing vigorous exercise reduces risk factors of type 2 diabetes, cardiovascular disease in children
October 15, 2018 - First-of-its-kind study to test a personalized vaccine in cancer patient
October 15, 2018 - Extension trial assesses benefit of switching from flash monitoring to RT-CGM for hypoglycemia
October 15, 2018 - Half of parents say young children are afraid of doctor’s visits
October 15, 2018 - Study shows how fingerprint-based drug screening works on the living and deceased
October 15, 2018 - Study reveals potential to monitor progression of Alzheimer’s disease by measuring brain antioxidant levels
October 15, 2018 - FDA Approves Xarelto to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)
October 15, 2018 - Promising new therapeutic approach against Ebola virus identified
October 15, 2018 - Study unravels how cancer stem cells use normal genes in abnormal ways
October 15, 2018 - Healthcare systems fail to deliver at affordable prices finds report
October 15, 2018 - Intensive BP Therapy in Diabetes May Lower Risk for CV Events
October 15, 2018 - Muscle relaxants increase risk of respiratory complications
October 15, 2018 - Female birds become more promiscuous after hatchings fail in the first breeding attempt
October 15, 2018 - Humans occupied Madagascar thousands of years later than previously thought
October 15, 2018 - Is Kidney Dialysis Always Needed When Septic Shock Strikes?
October 15, 2018 - Study shows invasive lung cancer surgery can lead to long-term opioid use
October 15, 2018 - Sugar, a “sweet” tool to understand brain injuries
October 14, 2018 - King’s commemorates activities and research on World Arthritis Day
October 14, 2018 - Humana and VFW NY team up on Stop 22 initiative to increase awareness of veterans committing suicide
October 14, 2018 - Water fluoridation contributes to urinary fluoride levels in pregnant women in Canada
October 14, 2018 - Study of children in Romanian orphanages tells cautionary tale about family separation
October 14, 2018 - Previous Endologix AFX Safety Notice classified by FDA as Class I recall
October 14, 2018 - Legal scholars sound alarm on academies’ report about returning research results to participants
October 14, 2018 - UNIST selects six extraordinary scholars to be induced as ‘Rising-star Distinguished Professor’
October 14, 2018 - Scientists find new way to help asthmatics breathe more easily
October 14, 2018 - New ‘gag rule’ may adversely impact health care of pregnant women
October 14, 2018 - Rosacea – Genetics Home Reference
October 14, 2018 - When the fighting crosses the line
October 14, 2018 - New findings could benefit patients with triple-negative breast cancer
October 14, 2018 - UK Biobank provides wealth of information for further genetic studies
October 14, 2018 - KHN’s ‘What the Health?’ Falling premiums and rising political tensions
October 14, 2018 - Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
October 14, 2018 - Tailored drug cocktails offer hope to kids with aggressive brain tumors
October 14, 2018 - Common gene variants linked to migraine risk in African-American children
October 14, 2018 - Funding requests are being accepted by BlueCross BlueShield of Tennessee Community Trust
October 14, 2018 - Using pulsed electric fields in cancer therapy
October 14, 2018 - Major Childbirth Complications More Likely for Black Women
October 14, 2018 - Young cancer survivors at greater risk of mental health disorders
October 14, 2018 - Common herbicide compound could help fight hospital-acquired fungal infections
October 14, 2018 - Alterations in genes encoding proteins contribute to ADHD development
October 14, 2018 - New patient-centric website launched in Europe to empower people with chronic conditions
October 14, 2018 - Antimicrobial signaling molecule has lower activity against hepatitis C virus in most humans
October 14, 2018 - Genomic dark matter activity connects Parkinson’s and psychiatric diseases
October 14, 2018 - Cornell dots equipped with antibody fragments offer a new cancer weapon
October 14, 2018 - Addressing social and cultural factors is key to reducing burden of type 2 diabetes
October 14, 2018 - Study reveals why females age more slowly than males
October 14, 2018 - DNA vaccine shown to provide long-term protection from Ebola
October 14, 2018 - Gene therapy shown to remove core component of Parkinson’s disease
October 14, 2018 - Obamacare premiums dip for first time. Some call it a correction
October 14, 2018 - Scientists use haploid stem cells to produce mice with same-sex parents
October 14, 2018 - New transgenic mouse model sheds light on biological causes of Parkinson’s disease
Including Drug to Same old Care Would possibly Extend Lymphoma Survival

Including Drug to Same old Care Would possibly Extend Lymphoma Survival

image_pdfDownload PDFimage_print

HealthDay news image

WEDNESDAY, Sept. 27, 2017 (HealthDay Information) — Lengthy-term remedy with the drug rituximab (Rituxan) might lengthen the lives of a few sufferers with an extraordinary type of blood most cancers, a brand new medical trial unearths.

The illness, referred to as mantle-cell lymphoma, is usually incurable. However quite a lot of therapies can extend other people’s lives. Some sufferers, as an example, are in a position to go through chemotherapy to wipe out the most cancers cells, adopted by way of a stem cellular transplant — to revive customary blood cells.

However whilst that means will also be efficient for some time, maximum sufferers see the most cancers come again.

So the brand new trial, funded by way of Rituxan maker Roche, checked out whether or not an extra step may assist: Having sufferers take Rituxan for 3 years following their stem cellular transplant.

Total, researchers discovered, the strategy did enhance sufferers’ outlook. After 4 years, 83 p.c of rituximab sufferers had been nonetheless alive and progression-free — as opposed to 64 p.c of sufferers who had same old remedy on my own.

Professionals mentioned the findings must have a direct have an effect on on sufferers’ remedy.

“This must be regarded as a brand new same old of care,” mentioned Dr. Anas Younes, leader of the lymphoma carrier at Memorial Sloan Kettering Most cancers Middle, in New York Town.

Alternatively, there are considerations with the long-term use of rituximab, consistent with Younes, who wasn’t concerned within the learn about.

The drug suppresses the immune device, so infections are at all times a possibility, he famous.

“However,” Younes added, “the advantages appear to outweigh the dangers.”

Dr. Steven Le Gouill, of Nantes Scientific College, in France, led the learn about.

He agreed that “rituximab repairs” — the usage of it long-term, after a stem cellular transplant — must turn into a brand new same old.

“The achieve in the case of total survival must inspire hematologists to prescribe rituximab repairs for transplanted sufferers,” Le Gouill mentioned.

Mantle-cell lymphoma is one in every of about 70 subtypes of non-Hodgkin lymphoma, consistent with the Leukemia & Lymphoma Society. In the USA, about four,200 individuals are identified with the illness every 12 months — maximum regularly, older males.

Medical doctors have lengthy used rituximab to regard sure cancers, together with mantle-cell lymphoma. The drug is a lab-engineered antibody that latches onto a protein on white blood cells (lymphocytes) known as B cells; the ones are the cells which are affected in mantle-cell lymphoma.

Because it stands, rituximab is used in conjunction with high-dose chemotherapy medicine to wipe out the cancerous B cells. Some sufferers then go through an “autologous” stem cellular transplant. That implies they’ve a few of their very own blood-forming stem cells got rid of prior to their drug routine; in a while, the stem cells are infused again into the frame, to revive new, wholesome blood cells.

Some sufferers — together with those that are older and frail — can not have a transplant.

However different analysis has proven that rituximab repairs, given after same old drug remedy to power out the most cancers, can lengthen the ones sufferers’ lives, Younes mentioned.

The brand new findings display the similar is correct for sufferers who do have a transplant.

The trial concerned 299 sufferers who had been more youthful than 66 once they had been identified with mantle-cell lymphoma. All underwent same old drug remedy, with rituximab and chemotherapy. Maximum — 86 p.c — spoke back neatly sufficient to go through a stem cellular transplant.

Part of the sufferers had been then randomly assigned to a few years of rituximab repairs remedy, receiving IV infusions of the drug each two months. The remaining had been adopted up with same old care.

After 4 years, 89 p.c of rituximab sufferers had been nonetheless alive, in comparison with 80 p.c within the comparability staff, the investigators discovered.

The rituximab sufferers had been additionally much more likely to stay freed from a most cancers relapse, or severe negative effects — together with critical infections and allergies: That was once true of 79 p.c of rituximab sufferers, as opposed to 61 p.c of sufferers on same old care.

In line with Le Gouill, “Rituximab repairs after stem cellular transplant is one new weapon within the arsenal to struggle towards mantle-cell lymphoma.”

He famous that different therapies were lately authorized — oral medicine that focus on abnormalities at the most cancers cells — whilst nonetheless others are in construction.

Like different antibody medicine, rituximab is pricey — operating 1000’s of greenbacks per thirty days after medical institution fees, consistent with a printed record. Repayment “might be a topic in some nations,” Le Gouill famous.

However, he added, the associated fee needs to be weighed towards the truth that the drug lengthens sufferers’ lives and has “low toxicity.”

Younes mentioned that the “vital message” from the findings is that sufferers’ survival time is constant to enhance.

The learn about findings had been printed Sept. 28 within the New England Magazine of Medication.

SOURCES: Steven Le Gouill, M.D., Ph.D., hematology carrier, Nantes Scientific College, Nantes, France; Anas Younes, M.D., leader, lymphoma carrier, Memorial Sloan Kettering Most cancers Middle, New York Town; Sept. 28, 2017, New England Magazine of Medication

Information tales are written and equipped by way of HealthDay and don’t replicate federal coverage, the perspectives of MedlinePlus, the Nationwide Library of Medication, the Nationwide Institutes of Well being, or the U.S. Division of Well being and Human Products and services.

Tagged with:

About author

Related Articles